| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Busulfan | 37 | 2024 | 764 | 4.690 |
Why?
|
| Vidarabine | 14 | 2024 | 1341 | 2.100 |
Why?
|
| RNA Helicases | 17 | 2005 | 101 | 1.960 |
Why?
|
| Adenine Nucleotides | 10 | 2016 | 351 | 1.550 |
Why?
|
| Arabinonucleosides | 10 | 2016 | 437 | 1.450 |
Why?
|
| Nuclear Proteins | 27 | 2014 | 3343 | 1.390 |
Why?
|
| Leukemia, Myeloid, Acute | 14 | 2024 | 6915 | 1.350 |
Why?
|
| Transplantation Conditioning | 17 | 2022 | 2238 | 1.330 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2017 | 588 | 1.170 |
Why?
|
| Melphalan | 14 | 2023 | 834 | 1.090 |
Why?
|
| Lymphoma | 7 | 2017 | 1467 | 1.050 |
Why?
|
| Agaricales | 2 | 2022 | 11 | 1.010 |
Why?
|
| Drug Synergism | 13 | 2022 | 1313 | 1.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2023 | 15862 | 1.000 |
Why?
|
| Epigenesis, Genetic | 4 | 2016 | 1399 | 0.980 |
Why?
|
| Deoxycytidine | 12 | 2020 | 1353 | 0.970 |
Why?
|
| Cell Nucleolus | 12 | 2008 | 89 | 0.950 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 17 | 2024 | 6550 | 0.930 |
Why?
|
| Sulfonamides | 5 | 2024 | 1823 | 0.890 |
Why?
|
| Plant Extracts | 2 | 2022 | 215 | 0.860 |
Why?
|
| Alkylating Agents | 2 | 2022 | 78 | 0.860 |
Why?
|
| Cyclophosphamide | 5 | 2024 | 3001 | 0.850 |
Why?
|
| Phosphoproteins | 8 | 2005 | 1152 | 0.850 |
Why?
|
| Apoptosis | 16 | 2024 | 7591 | 0.850 |
Why?
|
| DNA Damage | 10 | 2022 | 1954 | 0.820 |
Why?
|
| Cladribine | 3 | 2024 | 233 | 0.820 |
Why?
|
| Hematologic Neoplasms | 5 | 2022 | 1870 | 0.800 |
Why?
|
| Cell Line, Tumor | 21 | 2024 | 14551 | 0.790 |
Why?
|
| Multiple Myeloma | 5 | 2023 | 2138 | 0.770 |
Why?
|
| Reactive Oxygen Species | 4 | 2022 | 987 | 0.730 |
Why?
|
| RNA, Ribosomal | 6 | 2008 | 83 | 0.700 |
Why?
|
| Membrane Potential, Mitochondrial | 5 | 2021 | 133 | 0.690 |
Why?
|
| Depsipeptides | 2 | 2016 | 78 | 0.680 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2022 | 612 | 0.680 |
Why?
|
| RNA Nucleotidyltransferases | 5 | 1998 | 39 | 0.650 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 204 | 0.640 |
Why?
|
| Fluoresceins | 1 | 2017 | 73 | 0.600 |
Why?
|
| Cell Proliferation | 6 | 2022 | 7226 | 0.590 |
Why?
|
| Graft vs Host Disease | 8 | 2024 | 2638 | 0.580 |
Why?
|
| Hydroxamic Acids | 7 | 2016 | 442 | 0.570 |
Why?
|
| Drug Interactions | 2 | 2018 | 553 | 0.570 |
Why?
|
| Signal Transduction | 9 | 2021 | 11965 | 0.560 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 923 | 0.550 |
Why?
|
| Molecular Sequence Data | 27 | 2005 | 6089 | 0.530 |
Why?
|
| DNA Repair | 3 | 2022 | 1872 | 0.530 |
Why?
|
| RNA, Ribosomal, 28S | 2 | 2005 | 11 | 0.510 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 4 | 1999 | 54 | 0.510 |
Why?
|
| RNA, Ribosomal, 18S | 2 | 2005 | 25 | 0.500 |
Why?
|
| Antineoplastic Agents | 8 | 2022 | 14289 | 0.500 |
Why?
|
| HeLa Cells | 21 | 2008 | 1643 | 0.500 |
Why?
|
| Drug Combinations | 3 | 2024 | 621 | 0.490 |
Why?
|
| Amino Acid Sequence | 21 | 2005 | 4233 | 0.490 |
Why?
|
| Leukemia, Myeloid | 2 | 2009 | 941 | 0.470 |
Why?
|
| Flow Cytometry | 3 | 2017 | 3033 | 0.470 |
Why?
|
| RNA | 7 | 2003 | 1013 | 0.470 |
Why?
|
| Cloning, Molecular | 15 | 2005 | 1213 | 0.420 |
Why?
|
| Base Sequence | 17 | 2013 | 4917 | 0.420 |
Why?
|
| Humans | 87 | 2024 | 261506 | 0.410 |
Why?
|
| Myeloablative Agonists | 4 | 2022 | 384 | 0.400 |
Why?
|
| Mandibulofacial Dysostosis | 3 | 2005 | 16 | 0.400 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2020 | 566 | 0.390 |
Why?
|
| Sequence Homology, Amino Acid | 9 | 2005 | 997 | 0.390 |
Why?
|
| DNA Methylation | 2 | 2018 | 2669 | 0.390 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3230 | 0.390 |
Why?
|
| Carrier Proteins | 6 | 2001 | 2022 | 0.380 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2008 | 703 | 0.380 |
Why?
|
| Caspase 3 | 2 | 2022 | 471 | 0.370 |
Why?
|
| Genes | 6 | 2002 | 491 | 0.370 |
Why?
|
| Dactinomycin | 5 | 2004 | 145 | 0.370 |
Why?
|
| Tumor Cells, Cultured | 13 | 2017 | 5395 | 0.370 |
Why?
|
| Cross-Linking Reagents | 1 | 2010 | 153 | 0.360 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2016 | 5178 | 0.360 |
Why?
|
| Azacitidine | 3 | 2016 | 1149 | 0.350 |
Why?
|
| Genes, cdc | 1 | 2009 | 81 | 0.350 |
Why?
|
| Recombinant Fusion Proteins | 11 | 2004 | 1555 | 0.350 |
Why?
|
| Luminescent Proteins | 2 | 2002 | 289 | 0.340 |
Why?
|
| Hodgkin Disease | 4 | 2022 | 1429 | 0.330 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 1360 | 0.320 |
Why?
|
| DNA, Ribosomal | 2 | 2005 | 103 | 0.310 |
Why?
|
| Phthalazines | 2 | 2022 | 253 | 0.310 |
Why?
|
| Nucleosides | 2 | 2022 | 60 | 0.310 |
Why?
|
| Xenopus laevis | 2 | 2005 | 270 | 0.310 |
Why?
|
| Chromatin | 3 | 2022 | 942 | 0.300 |
Why?
|
| RNA Precursors | 2 | 2005 | 137 | 0.300 |
Why?
|
| DNA, Complementary | 7 | 2005 | 869 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2014 | 1823 | 0.290 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2017 | 83 | 0.290 |
Why?
|
| Cytotoxins | 2 | 2020 | 66 | 0.290 |
Why?
|
| Down-Regulation | 4 | 2005 | 2074 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 3639 | 0.280 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2015 | 430 | 0.280 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2022 | 170 | 0.280 |
Why?
|
| Phosphofructokinase-1 | 4 | 1989 | 13 | 0.280 |
Why?
|
| Exons | 4 | 2004 | 1328 | 0.270 |
Why?
|
| Nucleic Acid Conformation | 3 | 2003 | 279 | 0.270 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 479 | 0.270 |
Why?
|
| Ribosomes | 2 | 2003 | 147 | 0.270 |
Why?
|
| Benzoates | 2 | 2024 | 136 | 0.260 |
Why?
|
| Toyocamycin | 3 | 2002 | 5 | 0.260 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 2045 | 0.260 |
Why?
|
| RNA, Messenger | 10 | 2016 | 6150 | 0.260 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2008 | 560 | 0.260 |
Why?
|
| Ribosomal Proteins | 1 | 2005 | 118 | 0.250 |
Why?
|
| Xenopus Proteins | 1 | 2005 | 185 | 0.250 |
Why?
|
| Pol1 Transcription Initiation Complex Proteins | 1 | 2004 | 11 | 0.250 |
Why?
|
| Hydrazines | 2 | 2024 | 208 | 0.250 |
Why?
|
| Transcription, Genetic | 6 | 2005 | 3154 | 0.250 |
Why?
|
| Cell Compartmentation | 2 | 2002 | 76 | 0.250 |
Why?
|
| Caspases | 2 | 2022 | 661 | 0.250 |
Why?
|
| Thiotepa | 1 | 2024 | 118 | 0.240 |
Why?
|
| DEAD-box RNA Helicases | 5 | 2008 | 255 | 0.240 |
Why?
|
| DNA-Binding Proteins | 5 | 2014 | 4821 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2018 | 4938 | 0.230 |
Why?
|
| Phosphorylation | 6 | 2022 | 4804 | 0.230 |
Why?
|
| Poly ADP Ribosylation | 1 | 2022 | 9 | 0.220 |
Why?
|
| Epitopes | 3 | 1997 | 685 | 0.220 |
Why?
|
| Eukaryotic Cells | 1 | 2002 | 45 | 0.210 |
Why?
|
| Reishi | 1 | 2022 | 2 | 0.210 |
Why?
|
| Anthracenes | 1 | 2022 | 48 | 0.210 |
Why?
|
| Cell Survival | 3 | 2017 | 3045 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 8873 | 0.210 |
Why?
|
| Autoantigens | 2 | 1996 | 234 | 0.210 |
Why?
|
| RNA-Binding Proteins | 6 | 2001 | 984 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 3552 | 0.200 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2021 | 45 | 0.200 |
Why?
|
| Oligonucleotides, Antisense | 5 | 2005 | 248 | 0.200 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2018 | 801 | 0.200 |
Why?
|
| Blotting, Western | 10 | 2009 | 3536 | 0.200 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2001 | 71 | 0.200 |
Why?
|
| Connective Tissue Diseases | 2 | 2000 | 50 | 0.200 |
Why?
|
| Phytotherapy | 1 | 2022 | 110 | 0.190 |
Why?
|
| 3T3 Cells | 4 | 2002 | 355 | 0.190 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2021 | 142 | 0.190 |
Why?
|
| STAT5 Transcription Factor | 1 | 2022 | 214 | 0.190 |
Why?
|
| Geobacillus stearothermophilus | 3 | 1989 | 5 | 0.190 |
Why?
|
| Transplantation, Autologous | 7 | 2023 | 1914 | 0.190 |
Why?
|
| Piperazines | 2 | 2022 | 2101 | 0.190 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2000 | 3 | 0.190 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 275 | 0.190 |
Why?
|
| Gene Silencing | 1 | 2003 | 837 | 0.190 |
Why?
|
| Indoles | 2 | 2016 | 1009 | 0.190 |
Why?
|
| Acetylcysteine | 1 | 2021 | 143 | 0.180 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2000 | 32 | 0.180 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2021 | 301 | 0.180 |
Why?
|
| Introns | 4 | 2002 | 432 | 0.180 |
Why?
|
| Biological Transport | 3 | 2017 | 597 | 0.180 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 334 | 0.180 |
Why?
|
| DNA Fragmentation | 1 | 2020 | 198 | 0.180 |
Why?
|
| Xenopus | 3 | 2005 | 219 | 0.180 |
Why?
|
| Chromosome Mapping | 2 | 2000 | 1471 | 0.170 |
Why?
|
| Protein Transport | 1 | 2002 | 734 | 0.170 |
Why?
|
| Cell Nucleus | 2 | 2002 | 1620 | 0.170 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 413 | 0.170 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 83 | 0.160 |
Why?
|
| beta Catenin | 1 | 2022 | 688 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2024 | 1471 | 0.150 |
Why?
|
| Ethacrynic Acid | 1 | 2017 | 9 | 0.150 |
Why?
|
| Ketoconazole | 1 | 2017 | 34 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1493 | 0.150 |
Why?
|
| Oocytes | 3 | 2005 | 414 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 1678 | 0.150 |
Why?
|
| Chlorambucil | 1 | 2017 | 26 | 0.150 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2016 | 287 | 0.150 |
Why?
|
| Animals | 22 | 2010 | 59536 | 0.150 |
Why?
|
| Aspartic Acid | 2 | 1995 | 126 | 0.150 |
Why?
|
| Protein Inhibitors of Activated STAT | 5 | 2002 | 26 | 0.140 |
Why?
|
| Neuropeptides | 1 | 1997 | 154 | 0.140 |
Why?
|
| Growth Inhibitors | 3 | 1994 | 149 | 0.140 |
Why?
|
| Gene Duplication | 1 | 2018 | 421 | 0.140 |
Why?
|
| DNA | 3 | 2022 | 2693 | 0.140 |
Why?
|
| Stomach Diseases | 1 | 1996 | 62 | 0.130 |
Why?
|
| Microinjections | 2 | 2005 | 96 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 846 | 0.130 |
Why?
|
| Histone Code | 1 | 2016 | 79 | 0.130 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 2979 | 0.130 |
Why?
|
| Nucleolus Organizer Region | 3 | 2004 | 17 | 0.130 |
Why?
|
| Tissue Distribution | 3 | 2003 | 875 | 0.130 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 354 | 0.130 |
Why?
|
| Everolimus | 1 | 2017 | 415 | 0.130 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2005 | 189 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2008 | 166 | 0.130 |
Why?
|
| Mice | 14 | 2008 | 34495 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10035 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 336 | 0.120 |
Why?
|
| Protein Binding | 8 | 2004 | 3438 | 0.120 |
Why?
|
| Cell Death | 1 | 2016 | 671 | 0.120 |
Why?
|
| Bortezomib | 1 | 2016 | 543 | 0.120 |
Why?
|
| tRNA Methyltransferases | 7 | 1998 | 15 | 0.120 |
Why?
|
| Genes, p53 | 1 | 2018 | 1090 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 4 | 2000 | 611 | 0.120 |
Why?
|
| Transfection | 6 | 2003 | 2944 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1350 | 0.120 |
Why?
|
| Gene Expression | 6 | 2009 | 3570 | 0.120 |
Why?
|
| Genes, Bacterial | 3 | 1989 | 236 | 0.110 |
Why?
|
| Arginine | 3 | 1998 | 500 | 0.110 |
Why?
|
| Cell Division | 6 | 2003 | 2489 | 0.110 |
Why?
|
| Adenosine Triphosphatases | 3 | 2003 | 435 | 0.110 |
Why?
|
| RNA, Antisense | 1 | 1992 | 69 | 0.110 |
Why?
|
| Cell Line | 4 | 2005 | 5114 | 0.110 |
Why?
|
| Sirolimus | 1 | 2017 | 814 | 0.110 |
Why?
|
| Niacinamide | 1 | 2014 | 421 | 0.110 |
Why?
|
| Survival Analysis | 7 | 2021 | 9180 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 1996 | 402 | 0.110 |
Why?
|
| Sequence Deletion | 5 | 2001 | 875 | 0.110 |
Why?
|
| Blotting, Northern | 3 | 2003 | 682 | 0.110 |
Why?
|
| Glutathione Transferase | 5 | 2003 | 359 | 0.110 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2012 | 126 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 361 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2018 | 1129 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2003 | 568 | 0.100 |
Why?
|
| Histones | 3 | 2016 | 1466 | 0.100 |
Why?
|
| Sequence Alignment | 2 | 2005 | 844 | 0.100 |
Why?
|
| Middle Aged | 15 | 2021 | 86204 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2022 | 2315 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 580 | 0.100 |
Why?
|
| DNA Primers | 1 | 2013 | 1399 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2018 | 1154 | 0.100 |
Why?
|
| Acetylation | 1 | 2011 | 508 | 0.090 |
Why?
|
| Thionucleotides | 3 | 1995 | 65 | 0.090 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 278 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.090 |
Why?
|
| Autoantibodies | 3 | 2000 | 576 | 0.090 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 310 | 0.090 |
Why?
|
| Isoenzymes | 2 | 2002 | 614 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2018 | 2054 | 0.090 |
Why?
|
| Mutation | 5 | 2005 | 15179 | 0.090 |
Why?
|
| Adult | 12 | 2019 | 77950 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 448 | 0.080 |
Why?
|
| Genes, Regulator | 1 | 1988 | 69 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 2843 | 0.080 |
Why?
|
| Codon | 1 | 1989 | 241 | 0.080 |
Why?
|
| Rabbits | 3 | 2010 | 957 | 0.080 |
Why?
|
| Kinetics | 3 | 2003 | 2049 | 0.080 |
Why?
|
| Epitope Mapping | 2 | 2000 | 108 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 2 | 2002 | 694 | 0.080 |
Why?
|
| Muscles | 1 | 1989 | 416 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2004 | 2216 | 0.080 |
Why?
|
| Recurrence | 4 | 2022 | 4758 | 0.080 |
Why?
|
| G2 Phase | 1 | 2008 | 206 | 0.080 |
Why?
|
| Molecular Weight | 2 | 2005 | 629 | 0.080 |
Why?
|
| Cell Separation | 1 | 2009 | 612 | 0.080 |
Why?
|
| Male | 14 | 2019 | 123000 | 0.070 |
Why?
|
| Protein Methyltransferases | 4 | 1994 | 45 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2004 | 1265 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 6009 | 0.070 |
Why?
|
| Nuclear Localization Signals | 2 | 2004 | 46 | 0.070 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 196 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 3472 | 0.070 |
Why?
|
| Silver | 2 | 1997 | 34 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2008 | 324 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2005 | 189 | 0.070 |
Why?
|
| Conserved Sequence | 2 | 2000 | 469 | 0.070 |
Why?
|
| Cell Membrane Permeability | 2 | 2016 | 122 | 0.060 |
Why?
|
| Staining and Labeling | 2 | 1997 | 429 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 392 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 2527 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1664 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2008 | 1764 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 1994 | 43 | 0.060 |
Why?
|
| Escherichia coli | 4 | 1997 | 1203 | 0.060 |
Why?
|
| Peptide Fragments | 3 | 1997 | 1271 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2010 | 1529 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 591 | 0.060 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2003 | 40 | 0.060 |
Why?
|
| Time Factors | 3 | 2018 | 12926 | 0.060 |
Why?
|
| Methylation | 1 | 2005 | 597 | 0.060 |
Why?
|
| Female | 13 | 2019 | 141928 | 0.060 |
Why?
|
| Aged | 9 | 2021 | 70117 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 1299 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 2796 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2024 | 12873 | 0.060 |
Why?
|
| Adolescent | 7 | 2018 | 31252 | 0.060 |
Why?
|
| Nuclear Matrix | 1 | 2002 | 21 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 1995 | 4367 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 43 | 0.050 |
Why?
|
| RNA, Double-Stranded | 1 | 2002 | 79 | 0.050 |
Why?
|
| Heterozygote | 1 | 2005 | 1020 | 0.050 |
Why?
|
| Transplantation, Haploidentical | 1 | 2022 | 125 | 0.050 |
Why?
|
| Pseudogenes | 1 | 2002 | 81 | 0.050 |
Why?
|
| Young Adult | 5 | 2018 | 21445 | 0.050 |
Why?
|
| Proteins | 2 | 2002 | 1963 | 0.050 |
Why?
|
| Gentamicins | 1 | 2002 | 90 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2021 | 32848 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2004 | 842 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2002 | 323 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 1121 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2000 | 28 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2004 | 2084 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2001 | 187 | 0.050 |
Why?
|
| Syndrome | 1 | 2004 | 1351 | 0.050 |
Why?
|
| Antigens, Neoplasm | 3 | 1993 | 1506 | 0.050 |
Why?
|
| Microscopy | 1 | 2002 | 182 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2001 | 1487 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2002 | 370 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2005 | 2483 | 0.050 |
Why?
|
| Sequence Analysis, Protein | 1 | 2000 | 81 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2000 | 549 | 0.040 |
Why?
|
| Cattle | 1 | 2001 | 783 | 0.040 |
Why?
|
| Binding, Competitive | 3 | 1999 | 300 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2002 | 584 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2024 | 1581 | 0.040 |
Why?
|
| Models, Biological | 2 | 2008 | 3254 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2003 | 1694 | 0.040 |
Why?
|
| Guanosine Triphosphate | 1 | 1997 | 90 | 0.040 |
Why?
|
| Binding Sites | 4 | 2001 | 2171 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2002 | 1144 | 0.040 |
Why?
|
| Carmustine | 1 | 2018 | 214 | 0.040 |
Why?
|
| Mitochondria | 2 | 2016 | 1282 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 445 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2002 | 834 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1021 | 0.040 |
Why?
|
| Zinc Fingers | 1 | 1998 | 205 | 0.040 |
Why?
|
| Magnesium | 1 | 1997 | 160 | 0.040 |
Why?
|
| Remission Induction | 2 | 2016 | 3569 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 889 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 2422 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1997 | 182 | 0.040 |
Why?
|
| COS Cells | 1 | 1997 | 377 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 362 | 0.040 |
Why?
|
| Protein Sorting Signals | 1 | 1996 | 44 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2001 | 3101 | 0.030 |
Why?
|
| Scleroderma, Systemic | 1 | 1997 | 134 | 0.030 |
Why?
|
| Phenotype | 2 | 2008 | 6295 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 2016 | 108 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2016 | 307 | 0.030 |
Why?
|
| Etoposide | 1 | 2018 | 870 | 0.030 |
Why?
|
| Macrophages | 1 | 2002 | 1304 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 5159 | 0.030 |
Why?
|
| Rats | 2 | 2002 | 6086 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1997 | 571 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2024 | 37905 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 14889 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1997 | 223 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 650 | 0.030 |
Why?
|
| Antibodies | 1 | 1997 | 838 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Kidney | 1 | 2003 | 2146 | 0.030 |
Why?
|
| Gene Deletion | 2 | 1998 | 1442 | 0.030 |
Why?
|
| Tumor Protein p73 | 1 | 2014 | 105 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 726 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2014 | 201 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 1391 | 0.030 |
Why?
|
| Restriction Mapping | 2 | 1990 | 264 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2002 | 5637 | 0.030 |
Why?
|
| Testis | 1 | 1997 | 717 | 0.030 |
Why?
|
| DNA, Antisense | 3 | 2002 | 42 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 1062 | 0.030 |
Why?
|
| Doxorubicin | 1 | 1999 | 3005 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 2352 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 1618 | 0.030 |
Why?
|
| Child | 3 | 2018 | 29154 | 0.030 |
Why?
|
| Cytarabine | 1 | 2018 | 1973 | 0.030 |
Why?
|
| Mucositis | 1 | 2012 | 148 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 660 | 0.020 |
Why?
|
| Maltose-Binding Proteins | 1 | 1990 | 13 | 0.020 |
Why?
|
| Alleles | 1 | 1997 | 2437 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1995 | 1489 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1998 | 929 | 0.020 |
Why?
|
| Trypsin | 1 | 1990 | 140 | 0.020 |
Why?
|
| Survival Rate | 2 | 2016 | 12221 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2008 | 769 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2010 | 228 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 573 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 1990 | 119 | 0.020 |
Why?
|
| Bacteriophage lambda | 1 | 1989 | 36 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 1382 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 1546 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6207 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2010 | 335 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 1989 | 68 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 10331 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2054 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1994 | 2283 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 1999 | 2927 | 0.020 |
Why?
|
| Methionine | 1 | 1988 | 159 | 0.020 |
Why?
|
| Alanine | 1 | 1988 | 240 | 0.020 |
Why?
|
| Amino Acids | 1 | 1990 | 728 | 0.020 |
Why?
|
| Peptides | 2 | 2008 | 1479 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1996 | 124 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1995 | 4744 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2001 | 621 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 1999 | 362 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 10001 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1375 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2002 | 46 | 0.010 |
Why?
|
| RNA, Fungal | 1 | 2001 | 21 | 0.010 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2001 | 11 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2002 | 156 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2001 | 93 | 0.010 |
Why?
|
| Poliovirus | 1 | 2001 | 52 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2002 | 4078 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2008 | 1682 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1997 | 15694 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2001 | 132 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 13658 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2001 | 331 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2001 | 220 | 0.010 |
Why?
|
| Luciferases | 1 | 2001 | 445 | 0.010 |
Why?
|
| RNA, Transfer | 1 | 1999 | 77 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 7789 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2001 | 435 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 21713 | 0.010 |
Why?
|
| Guanosine | 1 | 1997 | 22 | 0.010 |
Why?
|
| Ribonucleoproteins | 1 | 1998 | 123 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 1070 | 0.010 |
Why?
|
| Mycophenolic Acid | 1 | 1997 | 148 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1998 | 240 | 0.010 |
Why?
|
| Spodoptera | 1 | 1996 | 63 | 0.010 |
Why?
|
| Baculoviridae | 1 | 1996 | 86 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2001 | 810 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1996 | 73 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 1999 | 4053 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1996 | 329 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2002 | 1555 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1995 | 82 | 0.010 |
Why?
|
| DNA, Neoplasm | 2 | 1993 | 1910 | 0.010 |
Why?
|
| Mice, Nude | 2 | 1993 | 4307 | 0.010 |
Why?
|
| Melanoma, Amelanotic | 1 | 1993 | 9 | 0.010 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1993 | 67 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1995 | 396 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 1992 | 74 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 406 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1993 | 771 | 0.010 |
Why?
|
| Neoplasms | 1 | 1995 | 15193 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1992 | 1519 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1989 | 195 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 750 | 0.010 |
Why?
|
| Gene Library | 1 | 1989 | 294 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1993 | 1450 | 0.000 |
Why?
|
| Genetic Complementation Test | 1 | 1987 | 125 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2001 | 5270 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1989 | 1258 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1993 | 2359 | 0.000 |
Why?
|
| Melanoma | 1 | 1995 | 5317 | 0.000 |
Why?
|